AFFILIATIONS
1 Department of Medicine III, LMU University Hospital, LMU Medizin, Munich, Germany, Laboratory of Precision Immunotherapy, LMU University Hospital, LMU Medizin, Munich, Germany
2 Bavarian Cancer Center (BZKF), Munich, Germany, Department of Medicine III, LMU University Hospital, LMU Medizin, Munich, Germany, Laboratory of Translational Cancer Immunology, LMU University Hospital, LMU Medizin, Munich, Germany
3 Adult BMT and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States
4 Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, United States
5 Vall d’Hebron Institute of Oncology (VHIO), Department of Hematology, University Hospital Vall d’Hebron, Barcelona, Spain
6 Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumorimmunology, Berlin, Germany
7 Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne, University of Cologne, Cologne, Germany
8 Department of Internal Medicine 5 - Hematology & Oncology, University Hospital of Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
9 Adult BMT and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States
10 Adult BMT and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States, Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
11 Department of Medicine III, LMU University Hospital, LMU Medizin, Munich, Germany, Laboratory of Translational Cancer Immunology, LMU University Hospital, LMU Medizin, Munich, Germany
12 Department of Medicine III, LMU University Hospital, LMU Medizin, Munich, Germany, Laboratory of Precision Immunotherapy, LMU University Hospital, LMU Medizin, Munich, Germany
13 Department of Medicine III, LMU University Hospital, LMU Medizin, Munich, Germany, Laboratory of Translational Cancer Immunology, LMU University Hospital, LMU Medizin, Munich, Germany
14 Department of Medicine III, LMU University Hospital, LMU Medizin, Munich, Germany, Laboratory of Precision Immunotherapy, LMU University Hospital, LMU Medizin, Munich, Germany
15 Department of Medicine III, LMU University Hospital, LMU Medizin, Munich, Germany, Laboratory of Precision Immunotherapy, LMU University Hospital, LMU Medizin, Munich, Germany
16 Department of Medicine III, LMU University Hospital, LMU Medizin, Munich, Germany
17 Adult BMT and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States
18 Bavarian Cancer Center (BZKF), Munich, Germany, Department of Medicine III, LMU University Hospital, LMU Medizin, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and LMU University Hospital, Munich, Germany
19 Department of Internal Medicine 5 - Hematology & Oncology, University Hospital of Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, University of South Florida Morsani College of Medicine, Tampa, Florida, United States
20 Bavarian Cancer Center (BZKF), Munich, Germany, Department of Internal Medicine 5 - Hematology & Oncology, University Hospital of Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
21 Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne, University of Cologne, Cologne, Germany
22 Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumorimmunology, Berlin, Germany
23 Vall d’Hebron Institute of Oncology (VHIO), Department of Hematology, University Hospital Vall d’Hebron, Barcelona, Spain
24 Adult BMT and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States
25 Adult BMT and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States
26 Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, United States
27 Adult BMT and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States
28 Bavarian Cancer Center (BZKF), Munich, Germany, Department of Medicine III, LMU University Hospital, LMU Medizin, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and LMU University Hospital, Munich, Germany, Laboratory of Translational Cancer Immunology, LMU University Hospital, LMU Medizin, Munich, Germany
29 Bavarian Cancer Center (BZKF), Munich, Germany, Department of Medicine III, LMU University Hospital, LMU Medizin, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and LMU University Hospital, Munich, Germany, Laboratory of Precision Immunotherapy, LMU University Hospital, LMU Medizin, Munich, Germany
ABSTRACT
Introduction Previous studies suggested improved survival in female lymphoma patients receiving CD19-directed CAR-T cell therapy. However, the underlying biological mechanisms remain poorly defined. Here, we explored clinical features assosciated with sex and investigated immunologic drivers of sex-related survival disparities.
Methods We performed a retrospective multicenter study of 1,065 adult LBCL patients treated with CD19 CAR T cells across seven centers. PFS and OS were assessed using Kaplan-Meier estimates. Multivariable Cox regression models were performed, adjusting for sex, age, CAR-T product, number of treatment lines, ECOG and pre-lymphodepletion LDH and CRP. Baseline inflammatory risk groups were defined according to established inflammation-based scores including InflaMix clusters (Raj, Nat Med 2025), a simplified CRP/Ferritin-based score (Faramand, BCD 2024), and CAR-HEMATOTOX score (Rejeski, Blood 2021). To explore sex-related differences in longitudinal proteomic profiles, we analyzed prospectively collected pre- and post-infusion serum samples applying the Olink proximity extension assay platform (IO96 panel, 149 patients, 548 total samples).
Results The cohort included 429 females (40.3%) and 636 males (59.7%) with a median age of 64 years at infusion. The applied CAR-T products were axi-cel (55.3%), tisa-cel (24.6%) and liso-cel (20.1%). Age and distribution of product, treating center, number of prior therapy lines, bridging therapy and ECOG did not differ significantly between sexes. However, female patients showed decreased serum CRP (0.7 vs 0.8 mg/dl, p<0.001) and ferritin (264 vs 378 ng/ml, p<0.001) at lymphodepletion. Accordingly, females had less pronounced baseline inflammatory risk as assessed by InflaMix clusters (23,8%% vs 32,6%%, p=0.002) and CRP/Ferritin-based score (11.6% vs 19.1%, p=0.009). Of interest, while absolute CAR-HEMATOTOX scores were significantly lower in females (p=0.013), CAR-HEMATOTOX groups were comparable between sexes (36,2% vs 39,8%, p=0.3), as inflammatory markers were offset by more extensive anemia and neutropenia in females. Female sex was associated with improved PFS (median 20.3 vs 9.7 months, logrank p<0.001) and OS (median not reached vs 31.0 months, logrank p=0.016). Toxicity severity was comparable between sexes, with comparable rates of CRS, ICANS, ICAHT and infections. While NRM (subdistribution hazard ratio [sHR] 1.25, 95% CI 0.79-1.97, p=0.34) was comparable by sex, we noted an increased cumulative risk of relapse in male patients (sHR 1.44, 95% CI 1.14-1.82, p=0.003). In multivariable models, female sex remained independently associated with improved PFS (adjusted hazard ratio [aHR] 0.61, 95% CI 0.48-0.79; p<0.001) and OS (aHR 0.71, 95% CI 0.53-0.96; p=0.024). In subgroup analyses stratified by sex and inflammation, we noted consistently improved outcomes in females across both higher- and lower inflammation strata, although a trend was noted towards greater curve separation in patients with very high baseline CRP/ferritin values. Using age >50 versus ≤50 years as a surrogate for menopausal status, exploratory analyses did not identify differences in PFS or OS among female patients. Proteomic profiling revealed distinct sex-associated differences. Males demonstrated higher levels of protein expression of IL-6, IFN-γ, CXCL10, CXCL11 and CD4 compared to females, consistent with early Th1 and innate inflammatory activation. In parallel, PD-L1 was also increased in males, suggesting concomitant induction of pathways associated with exhaustion, alongside immune activation. Notably, inflammatory and immune-regulatory signatures peaked early in males and subsequently declined, whereas females displayed a more stable proteomic profile over time, potentially reflecting a more sustained immune response. These findings were accompanied by significantly enhanced CAR T-cell expansion in males compared to females within a subset of patients with elevated CRP levels (p=0.001, n=25).
Conclusions In this multicenter LBCL cohort, female sex emerged as an independent predictor of improved survival after CD19 CAR-T therapy. The association with decreased baseline ifnlammation and distinct immune trajectories in female patients suggests that inflammatory host state shapes sex-related differences in CAR-T efficacy. Future studies should determine whether sex-informed inflammation-directed strategies before CAR T-cell therapy can mitigate outcome disparities.